Medtronic's Resolute stent performs well in new study; London researchers get drugs across blood-brain barrier;

> Medtronic's ($MDT) Resolute drug-eluting stent showed no increased safety risk in a study of patients who discontinued antiplatelet therapy one month into their treatment--the results allow for an update to Resolute's CE mark but don't affect U.S. regulation. Release

> Researchers at the University College in London have found a way to deliver modified peptide drugs across the blood-brain barrier by attaching them to a group of fat molecules in nanofibers. Story

> HylaPharm, a spinout from the University of Kansas, is developing a cancer-drug delivery mechanism using nanoparticles that could make cancer treatments safer and more effective, most notably those that mestastize in the lymph nodes. More

> As part of its needle-free glucose monitoring system, Symphony, Echo Therapeutics ($ECTE) secured a patent for its Prelude SkinPrep System, the skin permeation component of the method. Release

> Drug delivery company Catalent broadened its global reach with a move to open two new facilities in China, focusing on its Softgel technologies and clinical supply solutions businesses. Release

Suggested Articles

Takeda forged a feasibility pact to see whether it could pair a plasma-based therapy with Elektrofi's microparticle delivery tech.

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.